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which is critical for neuromuscular junction formation and maintenance 6 but also as a coreceptor for other ligands, such as sclerostin, Wise, and Dkk1 (Dickkopf-related protein 1). 7, 8 Lrp4 is expressed in various tissues, including the brain. However, its function in the brain remains largely unknown. Lrp4 is predominantly expressed in astrocytes, and Lrp4 loss in mouse astrocytes reduces glutamatergic neurotransmission and epileptic response, 9 ,10 a response frequently associated with stroke. We, thus, asked whether Lrp4 plays a role in ischemia/stroke-induced brain damage response.
Here, we present evidence for astrocytic Lrp4's function in promoting ischemia/stroke-induced neuronal death and reactive astrogliosis. Lrp4 is increased in response to ischemia/ stroke, and Lrp4 knockout (KO) in astrocytes increased ATP release and the production of ATP derivative, adenosine. Inhibition of ATP-P 2 X 7 R (P2X purinoceptor 7) or adenosine-A 2A R (adenosine A2A receptor) signaling by their antagonists diminished Lrp4-KO's protective effect in response to ischemia/stroke. Taken together, these results demonstrate that Lrp4 plays an important role in ischemia/stroke response possibly by suppressing ATP release from astrocytes.
Methods
Details on generation of different mouse lines, methods of lesion volume measurement, Western blot, immunocytochemistry, quantitative real-time polymerase chain reaction, primary cultures of astrocytes and neurons, and oxygen and glucose deprivation (OGD) exposure were described in the online-only Data Supplement. We will make our data, analytic methods, and study materials available to other researchers directly if they request it.
Animals
Male mice used for all the experiments were 2 to 3 months of age with 24 to 30 g of body weight. The number of animals per genotype per assay was calculated based on power analysis. Nine animals per group were targeted to reach 80% power at a significance level of <0.05, assuming 20% difference in both mean and SD at the 95% confidence level. Mice with the same identity (genotype and sex) were randomly selected. Mouse identity (genotype) was determined by a third party and blinded to experimenters. All the experimental procedures were approved by the Institutional Animal Care and Use Committee of the Augusta University.
Photothrombotic Ischemia
Mouse neocortex injury was induced by photothrombotic ischemia as described previously. 11 Briefly, mice anesthetized by ketamine (100 mg/kg) and xylene (10 mg/kg) were injected with 1% rose Bengal (IP; 100 mg/kg; Sigma). Ten minutes after rose Bengal injection, the sensorimotor cortex region, which includes a large part of the sensorimotor cortex centered ≈2 mm lateral to the bregma, was exposed to cold light for 15 minutes. Sham-injected mice received the same operation except for Rose Bengal injection.
Middle Cerebral Artery Occlusion Model of Ischemic Stroke
The transient (2 hours) middle cerebral artery occlusion was induced in anesthetized adult male mice by using an intraluminal vascular occlusion as described previously. 12 Briefly, mice were anesthetized with 1% to 1.5% isoflurane in a medical air (20% oxygen, 80% nitrogen; flow rate=0.7 L/min). An incision along midline skin on the mouse neck was made to expose the right common carotid artery, external carotid artery, and internal carotid artery. A small incision at the end of external carotid artery stump was made. A nylon suture (Ethilon nylon suture, 6-0) with its tip rounded by heating near a flame was inserted into the external carotid artery through the lumen of internal carotid artery to block the origin of middle cerebral artery, which was maintained inside for 2 hours. After 2 hours of the arterial occlusion, blood flow was restored by the withdrawal of the nylon suture.
Functional Tests
Modified neurological severity score evaluation, adhesive removal test, and foot fault test were performed before ischemia and at days 1, 3, 7, and 14 after ischemia/stroke, as described previously. 13 Neurological function was graded on a scale of 0 to 14 (normal score 0; maximal deficit score 14) with one point awarded for the exhibition of specific abnormal behavior or for lack of a tested reflex. A greater impairment of normal function results in a higher score.
TTC Staining
The forebrains were sliced into 750-μm-thick coronal sections. The sections were stained with 2% (wt/vol) TTC (2,3,5-triphenyltetrazolium chloride; Sigma-Aldrich) saline solution at 37°C for 10 minutes, fixed with 4% paraformaldehyde for 15 minutes, and washed with PBS for 5 minutes for 3 times.
Measurements of ATP, Adenosine, Glutamate, and d-Serine
ATP was measured by a luciferase reaction where light (560 nm) was emitted when d-luciferin is converted to oxyluciferin using the ENLITEN ATP Assay System (FF2000; Promega).
14 Adenosine is measured by using the Adenosine Assay Kit (K327-100; Bio Vision). Glutamate was measured by using the Glutamate Colorimetric Assay Kit (K629-100; Bio Vision). d-Serine was measured by ELISA.
Statistical Analysis
Statistical analyses were performed by using Prism 5 for Student t test and 1-way ANOVA. All values were expressed as mean±SEM. The data were considered to be significant when P<0.05. Normally distributed data were analyzed by ANOVA followed by Bonferroni or Fisher least significant difference post hoc tests as necessary. Student t test was used to compare pairs of means. To access Lrp4's potential role in ischemia/stroke response, we first examined Lrp4 protein level in mouse cortex. The photothrombotic ischemic model was used to induce local cortical ischemia/stroke ( Figure 1A ). Western blot showed an increase of Lrp4 in homogenates from the penumbra region at days 3 and 7 after ischemia/stroke ( Figure 1B ). Real-time polymerase chain reaction also showed a time-dependent increase in Lrp4's mRNAs after ischemia/stroke ( Figure 1B) , suggesting a transcriptional mechanism underlying ischemia induction of Lrp4 expression. The transcriptional increase of Lrp4 was further tested by LacZ staining analysis of the cortical brain in muscle-rescued Lrp4 null mutant, mr-Lrp4
Results
Increase of Lrp4 Expression in
LacZ/LacZ ( Figure IA in the online-only Data Supplement). In this mutant line, LacZ expression is under the control of endogenous Lrp4 promoter. 9 In response to ischemia/stroke, the LacZ activity was selectively elevated in the penumbra region ( Figure IB in the online-only Data Supplement), providing additional evidence for an increase of Lrp4's transcription in response to ischemia/stroke. These results demonstrate an increased Lrp4 expression in response to ischemia/stroke.
To determine Lrp4's function in ischemia/stroke response, we took advantage of Lrp4 mutant mice, Lrp4 GFAP-Cre . Lrp4's expression in the mutant brain was nearly completely depleted ( Figure IIA in the online-only Data Supplement). Photothrombotic ischemia induced a local cortical injury in both control and Lrp4 GFAP-Cre mice ( Figure 1C) . Intriguingly, the volume of the cortical brain injury was much less in Lrp4 GFAPCre mice than that of control mice ( Figure 1C ; Figure IIB in the online-only Data Supplement), suggesting a protective effect of Lrp4 deficiency. We then tested this view by using middle cerebral artery occlusion model. In agreement with photothrombotic ischemia model, less brain injury volume was detected in Lrp4 GFAP-Cre mice than those of controls ( Figure 1C ; Figure IIC in the online-only Data Supplement). We further tested this view by using modified neurological severity score, adhesive removal test, and foot fault test. Neurological functional impairments were significantly diminished after stroke in Lrp4
GFAP-cre mice, compared with control mice ( Figure 1D ), indicating a better motor sensory function in Lrp4 GFAP-Cre mice.
Reduction of Ischemia/Stroke-Induced Neuronal Death and Reactive Astrogliosis in Lrp4 GFAP-Cre Mice
To further evaluate the protective function in Lrp4 GFAP-Cre mice, we examined ischemia/stroke-induced neuronal death by terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) staining analysis. Two hours after ischemia/stroke, TUNEL-positive cells in the ischemic zone were obviously detected in the control cortex, which were largely reduced in the mutant ( We, thus, compared the astroglial response to ischemia/stroke between control and Lrp4 GFAP-Cre mice. On day 3 after ischemia/stroke, astrocytes, marked by GFAP (glial fibrillary acidic protein), were increased in penumbra region of the control cortex ( Figure 2C) . However, such ischemia/strokeinduced GFAP-labeled astrocytes were much lower in the mutant cortex than that of controls ( Figure 2C and 2D) , indicating a reduction of reactive astrogliosis in the Lrp4 mutant cortex. We further tested this view by performing the following experiments. First, we coimmunostained the injured control and mutant cortical brain sections with antibodies against GFAP and nestin because nestin is also a marker of immature and reactive astrocytes, in addition to neural stem/progenitor cells. 16 Indeed, nestin was largely coexpressed with GFAP in the control cortex, but little costaining was detected in the mutant brain ( Figure 2C and 2D ). This result is consistent with our previous data. Bromodeoxyuridine (BrdU) marks proliferative cells, a property in association with reactive astrocytes, 17 which was injected into the mice (50 mg/kg IP, once per 4 hours for 4 times), and the mice were euthanized 24 hours after the first injection. Coimmunostaining analysis showed that the proliferative reactive astrocytes (BrdU + and GFAP + cells compared with total BrdU + cells) were much lower in the mutant cortex than those of controls ( Figure 2C and 2D). Second, to investigate whether the reduction in reactive astrocytes in the injured mutant cortex was a consequence of impairment of astrocytic development, aldolase C-labeled astrocytes after stroke were tested. Although GFAP-marked reactive astrocytes were reduced in the mutant ischemic cortex, astrocytes labeled by antialdolase C antibody seemed to be unchanged ( Figure 2C and 2D ). In addition, the glial cells, labeled by anti-S100 staining ( Figure IIIA and IIIB in the online-only Data Supplement), and the blood vessels, viewed by anti-CD31 staining ( Figure IIIC and IIID in the online-only Data Supplement), seemed to be normal, suggesting a normal astrocyte development. ) mice in response to ischemia/stroke. Mice were subjected to ischemia/stroke by photothrombosis model. At day 2 after stroke, bromodeoxyuridine (50 mg/kg per 4 hours, 4 times) was injected, and mice were euthanized at day 3, and their brain sections were subjected to coimmunostaining analysis using indicated antibodies. A and B, Coimmunostaining analysis with antibodies against cleaved caspase 3 (a cell death marker) and NeuN (a neuronal marker). A, Representative images and (B) quantitative analysis (mean±SEM; n=6/group; *P<0.05). C and D, Coimmunostaining analyses of GFAP (glial fibrillary acidic protein)-marked reactive astrocytes with antibodies against Nestin (a marker for neural stem cells and reactive astrocytes), bromodeoxyuridine (a marker of proliferative cells), or aldolase C (a marker of astrocytes). Top, representative images. Bottom, Quantification analyses (mean±SEM; n=6/group; *P<0.05).
Taken together, these results demonstrate decreases in neuronal death and reactive astrogliosis in Lrp4 GFAP-Cre mice in response to ischemia/stroke, providing cellular evidence for a protective effect in Lrp4-KO mice.
Attenuation of Ischemia/Stroke-Induced Brain Injury in Astrocyte-Specific Lrp4 Knockout Mice
Although Lrp4 is largely expressed in astrocytes, 9 Lrp4
GFAP-Cre mice knocked out Lrp4's expression in nearly all types of brain cells, including astrocytes, neural stem cells, and neurons. 9 To determine in which cell type(s) that Lrp4 plays a crucial protective role in response to ischemia/stroke, we used Lrp4 GFAP-CreER mice were subjected to ischemia/stroke injury ( Figure 3A) . As a control, corn oil was injected into Lrp4 GFAP-CreER mice. As shown in Figure 3B , Lrp4 GFAP-CreER mice (IP tamoxifen), as that of Lrp4 GFAP-Cre mice, displayed a protective effect on the ischemic injury, with less injured brain volume. In contrast, Lrp4
Nex-Cre mice, which specifically knocked out Lrp4 gene in pyramidal neurons, showed little difference from their controls in response to ischemia/stroke. These results, thus, suggest that Lrp4 deficiency in astrocytes, but not in neurons, plays a protective role in response to stroke.
The astroglial response to ischemia/stroke were tested between control and Lrp4
GFAP-CreER
/Lrp4
Nex-Cre mice. GFAPlabeled astrocytes in penumbra region were much lower in the Lrp4 GFAP-CreER (IP tamoxifen) cortex than that of controls ( Figure 3C ). However, Lrp4
Nex-Cre mice showed little difference from their controls in response to ischemia/stroke ( Figure 3D ). These results indicated a reduction of reactive astrogliosis in Lrp4 GFAP-CreER cortex other than Lrp4 Nex-Cre cortex.
Reduction of OGD-Induced Neuronal Death by Condition Medium of Lrp4-Depleted Astrocytes
To understand how Lrp4 deficiency in astrocytes plays a protective role in response to ischemia/stroke, we examined whether Lrp4-deficient astrocytes are protective for neuronal survival in response to ischemia injury in culture. Astrocytes isolated from the P2 cerebral cortex of control and Lrp4 GFAP-Cre mice and neurons derived from E14.5 cerebral cortex in C57BL/6J mice were cultured separately. At day 5 to 7 of neuronal culture, 1 coverslip of neurons with 4 coverslips of astrocytes were cocultured in a 60-mm dish with maintenance medium ( Figure 4A ). One day later, neurons and astrocytes were exposed to OGD for 1, 2, and 3 hours. Neurons were then fixed, and their apoptosis was examined by TUNEL analysis. As shown in Figure 4B and 4C, less TUNEL-positive neurons were detected when neurons cocultured with Lrp4-deficient astrocytes than that of control astrocytes. These results, thus, suggest a crucial role for Lrp4-deficient astrocytes to protect neurons from OGDinduced cell death.
Increases in ATP and Adenosine Levels in Condition Medium of Lrp4-Deficient Astrocytes in Response to OGD
The astrocytic Lrp4's protective effect on neuronal survival may be mediated by soluble factors secreted from astrocytes because they did not directly contact with neurons in above coculture assays. We, thus, measured well-studied gliotransmitters, such as glutamate, d-serine, ATP, and adenosine, in the condition medium (CM) of astrocytes (wild type [WT] and Lrp4 mutant; Figure 5A ). 18 As shown in Figure 5B , little difference was detected for glutamate and d-serine levels between control and Lrp4 mutant astrocytes, but ATP and adenosine were significantly elevated in the CMs of mutant astrocyte cultures. On OGD treatment, glutamate, ATP, and adenosine were all increased. However, more dramatic increases in ATP and adenosine levels were detected in the CMs of Lrp4-deficient astrocytes than those of controls. These results, thus, implicate ATP/adenosine as potential mediators for the protective effect by Lrp4-deficient astrocytes.
Restore of OGD/Ischemia-Induced Neuronal Death by Inhibition of P 2 X 7 R and A 2A R Signaling
We then examined whether the increased ATP/adenosine contributes to the protective effect on neurons by Lrp4-deficient astrocytes. A740003, an antagonist for P 2 X 7 R and SCH58261, an antagonist for A 2A R were used in this experiment. As shown in Figure 6A , ATP release was significantly enhanced in the CM of Lrp4-deficient astrocytes, compared with that of WT controls. After OGD treatment, dramatic increases of ATP release were detected in the CM of Lrp4-deficient astrocytes, compared with that of WT controls. However, there is no significant difference in ATP release between Lrp4-deficient astrocytes and WT controls after OGD and A740003/ SCH58261 treatment. These results implicate ATP/adenosine as potential mediators for the protective effect by Lrp4-deficient astrocytes.
Then WT neurons were cocultured with control and Lrp4-deficient astrocytes in the presence of A740003 or SCH58261, respectively ( Figure 6B ). Cocultured cells were under the normal or OGD condition, and neuronal death was then evaluated by TUNEL staining analysis. As shown in Figure 6B , although neurons cocultured with Lrp4-deficient astrocytes showed a reduction in OGD-derived death, this protective effect was diminished by A740003 and SCH58261 treatments, suggesting a possible contribution of ATP-P 2 X 7 R or adenosine-A 2A R signaling to the protective effect in culture.
To test this view in vivo, Lrp4 GFAP-Cre mice were treated with A740003 (0.5 mg/kg IP; daily) or SCH58261 (2 mg/kg IP; daily) for 3 days ( Figure 6C ). Mice were subjected to the photothrombotic stroke injury, and their brain samples were analyzed 3 days after the brain injury. As shown in Figure 6C , both A740003 and SCH58261 reduced the protective effect in Lrp4 mutant mice, compared with WT controls. These results indicate that inhibiting P 2 X 7 R or A 2A R signaling prevents from Lrp4 deficiency-induced protective effect, providing an in vivo evidence for ATP-P 2 X 7 R or adenosine-A 2A R's contribution to Lrp4 deficiency-induced protective effect.
Stroke
January 2018
To understand how P 2 X 7 R or A 2A R contributes to the stroke response in control and Lrp4 mutant mice, we examined their protein levels in mouse brain in response to ischemia/stroke. Interestingly, Western blot showed an increase of A 2A R, but not P 2 X 7 R, in homogenates from the penumbra region of both control and Lrp4-KO mice at day 3 after ischemia/stroke Figure 3 . Attenuation of ischemia/stroke-induced brain injury in astrocyte-specific Lrp4 (low-density lipoprotein receptor-related protein 4)-knockout (KO) mice. Mice with indicated genotypes were subjected to ischemia/stroke by photothrombosis model. At day 3 after stroke, mice were euthanized, and their brain sections were subjected to Nissl staining (B) and immunostaining (C) analyses. A, Schematic of the time course for tamoxifen injection and ischemic stroke injury in astrocytic-specific Lrp4 conditional knockout (Lrp4 GFAP-CreER ) mice. Tamoxifen (100 mg/kg) was injected into Lrp4 GFAP-CreER mice at 2 months of age. Two weeks after tamoxifen injection, ischemia/stroke was induced by photothrombosis. Mice were subjected to the photothrombotic stroke, and Nissl staining was performed 3 days after stroke. As shown in Figure  VC in the online-only Data Supplement, A 2A R-KO mice showed more injury volume after ischemia/stroke compared with that of WT controls, consistent with previous report. 19, 20 As expected, A 2A R deficiency attenuated the protective effect of brain injury in Lrp4 GFAP-CreER mice, providing additional evidence for adenosine-A 2A R signaling's contribution to Lrp4-KO's protective effect. In line with this view, the reactive astrocytes marked by BrdU and GFAP costaining were also increased in Lrp4 In aggregate, these results suggest that the reduced neuronal death by OGD/stroke in the coculture with Lrp4-deficient astrocytes and in Lrp4 mutant mice is likely because of the increased ATP-P 2 X 7 R and adenosine-A 2A R signaling.
Discussion
Astrocytes play key roles in the physiology and pathology of the central nervous system, including brain injury. Lrp4 is mainly expressed in astrocytes in the brain. Here, we used ischemia/stroke model to investigate astrocytic Lrp4's function. We found that astrocyte-specific Lrp4-CKO mice (Lrp4 GFAP-CreER ) displayed less brain damage and reactive astrogliosis. Such a protective effect seemed to result from increased ATP release from Lrp4-KO astrocytes, and ATP derivative, adenosine, because inhibition of ATP-P 2 X 7 R or adenosine-A 2A R signaling by their antagonists diminished Lrp4-KO's protective effect. These results demonstrate a role of ATP release from astrocytes that is negatively regulated by Lrp4 and reveal an unrecognized mechanism/target to protect brain ischemic injury.
The conclusion that the astrocytic Lrp4 contributes to ischemia/stroke-induced neuronal death or brain injury response is based on the following observations. First, Lrp4 is mainly expressed in astrocytes, 9 and its expression is increased in the penumbra region of neocortex in response to ischemia/stroke. Second, both Lrp4 GFAP-Cre and Lrp4
GFAP-CreER
, but not Lrp4
Nex-Cre , show less brain injury after ischemia/stroke, including decreased neuronal death and reduced reactive astrogliosis. Third, Lrp4-KO astrocytes protect neurons from OGDinduced death when compared with that of control astrocytes.
How does astrocytic Lrp4 contribute to ischemia/strokeinduced brain injury? One hypothesis is that it promotes reactive astrogliosis in response to ischemia/stroke, which enhances brain injury. This hypothesis is in line with the observations that an impaired reactive astrogliosis in Lrp4 GFAP-CreER mice is tightly associated with the decreased neuronal injury response. Reactive astrogliosis frequently increases brain inflammation that is deleterious for neurons. 2 However, a chicken-egg issue exists, because reactive astrogliosis in the mutant mice could be a consequence and a cause of the neuronal injury response. It lacks convincing evidence to demonstrate whether Lrp4-KO in astrocytes impairs reactive astrogliosis earlier than that of neuronal death independent of the neuronal injury and whether reactive astrocytes promote neuronal injury in Lrp4
GFAP-CreER mice. These questions remain to be addressed in future. 
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An alternative hypothesis is that the astrocytic Lrp4 prevents ATP release and adenosine production, which are protective for neuronal death or injury. This hypothesis is supported by the following observations. First, ATP release from astrocytes and extracellular adenosine were increased by OGD and Lrp4 deficiency. Second, suppressing astrocytic ATP release by P 2 X 7 receptor antagonist, A740003, was capable of increasing neuronal death and injury response in culture and in vivo. Third, A 2A R levels were elevated in both control and Lrp4 mutant brain in response to ischemia/stroke. Fourth, inhibition of adenosine-A 2A R signaling by SCH58261 was able to restore ischemia/stroke-induced neuronal injury response and OGD-induced neuronal death. In light of these observations, we propose a working model depicted in the visual abstract. This hypothesis does not exclude reactive astrogliosis model, and both mechanisms may underlie astrocytic Lrp4 regulation of stroke response.
Our results indicate that both ATP-P 2 X 7 R and adenosine-A 2A R signaling seem to play a protective role in ischemia/ stroke-induced brain injury, raising questions on the underlying mechanisms. ATP-P 2 X 7 R and adenosine-A 2A R signaling may have an autocrine-positive effect on astrocytic ATP release in response to ischemia/OGD, resulting in a high level of extracellular ATP and its derivative, adenosine, which may prevent the toxic level of glutamate release from excitatory neurons. 21 This view is based on the following observations. P 2 X 7 receptor is reported to regulate astrocytic ATP release. 22 Treatments with a P 2 X 7 receptor antagonist, A740003, and A 2A R inhibitor, SCH58261, in Lrp4-deficient astrocytes prevent OGD-induced ATP release. Adenosine-A 1 R is found to suppress glutamate release from excitatory neurons, 9 and A 2A R is highly expressed in astrocytes and modulate astrocytic glutamate uptake. [23] [24] [25] High level of glutamate has excitatory toxicity. 26 However, this view also faces challenges. It has been reported that A 2A and P 2 X 7 receptors contribute to excessive excitotoxicity because their antagonists can reduce brain damage after ischemia/stroke. 27 These differential observations may be caused by a different source of ATP/adenosine and a different dose of ATP/adenosine. It is possible that ATP from astrocytes is protective, but ATP released from neurons or microglia may be toxic. Further investigations are necessary to resolve this issue.
In summary, we have found a protective effect on ischemia/stroke-induced cortical brain injury by Lrp4 deficiency in astrocytes. Such a protective effect may result from the increased ATP release from Lrp4-deficient astrocytes, revealing a potential target for therapeutic strategy development on ischemic brain injury.
